Novartis’ Alcon Gains ex-US Rights to ThromboGenics’ Ocriplasmin
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 3 (Table of Contents)
Published: 26 Mar-2012
DOI: 10.3833/pdr.v2012.i3.1704 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Alcon, Novartis’ ophthalmic division, has gained exclusive ex-US rights to commercialise ThromboGenics’ ocriplasmin for symptomatic vitreomacular adhesion in a deal potentially worth more than €375 M (US$489 M), including €75 M (US$98 M) upfront...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS